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Abstract
Background: The stromal microenvironment and particularly the macrophage component of primary tumors influence their
malignant potential. However, at the metastatic site the role of these cells and their mechanism of actions for establishment
and growth of metastases remain largely unknown.
Methodology/Principal Findings: Using animal models of breast cancer metastasis, we show that a population of host
macrophages displaying a distinct phenotype is recruited to extravasating pulmonary metastatic cells regardless of species
of origin. Ablation of this macrophage population through three independent means (genetic and chemical) showed that
these macrophages are required for efficient metastatic seeding and growth. Importantly, even after metastatic growth is
established, ablation of this macrophage population inhibited subsequent growth. Furthermore, imaging of intact lungs
revealed that macrophages are required for efficient tumor cell extravasation.
Conclusion/Significance: These data indicate a direct enhancement of metastatic growth by macrophages through their
effects on tumor cell extravasation, survival and subsequent growth and identifies these cells as a new therapeutic target for
treatment of metastatic disease.
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Introduction
Metastatic disease is the major cause of cancer mortality. This
fact indicates that metastases are refractory to current treatments
such as the traditional modalities of irradiation and chemotherapy
as well as the more recent targeted biological therapies. The failure
of available treatments suggests that the biological mechanisms
that underlie metastatic disease are poorly understood. It is known
however, that metastasis is a multi-step process with tumor cells
needing to escape from the primary site as well as arriving and
prospering at distant sites [1]. In the first steps oncogenic
mutations in the tumor cells together with the development of a
supportive microenvironment leads to the ability of the tumor cells
to invade through the stroma and intravasate into the hematog-
enous or lymphatic system. These are significant rate limiting steps
in the metastatic process [1]. But successful intravasation is only
the beginning of the cell’s odyssey. Cells destined to produce
metastases must survive in the circulatory system, and the distal
events of initial seeding and persistent growth in the target organ
are also highly inefficient. In fact, senescence or apoptosis of tumor
cells entering target organs prevents the lethal spread of the vast
majority of intravasated tumor cells [2,3,4].
The ‘‘seed’’ and ‘‘soil hypothesis by Paget [5] was an early
attempt to explain the metastatic process. In its modern guise, the
hypothesis proposes that tumor cells have to accumulate sufficient
mutations to become metastatic while the target site has to be
permissive to allow the appropriately mutated tumor cell to survive
and prosper [5,6]. Recently, many changes in the tumor cell have
been identified that allow them to become metastatic and to have
a particular trophism to a tissue such as bone or liver [7]. Studies
in primary tumors however, have also revealed major roles for the
microenvironment in modulating malignancy including significant
roles for resident cells such as fibroblasts and adipocytes, as well as
haematopoietic cells [8,9,10,11,12,13]. Genetic experiments
whereby particular classes of cells are ablated in the tumor have
revealed major roles for mast cells and macrophages in tumor
progression and for macrophages in promoting metastasis
[14,15,16]. In the latter case macrophages stimulates tumor cell
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migration, invasion and intravasation in mouse models of breast
cancer [8,9]. These data strongly suggest an active role for an ever-
changing microenvironment in the malignant evolution of primary
tumors, with macrophages being major players.
Macrophage interactions with metastases have been observed,
however their contribution to the metastasis process has been
controversial [17,18]. Recent studies have shown that myeloid
cells are involved in primary tumor directed metastatic tumor cell
homing to target organs through the creation of preferred sites
known as pre-metastatic niches [19,20]. Studies have also shown
that tumor cell secreted factors enhance Lewis lung carcinoma
metastasis through their effects on Toll-like receptor 2 signaling in
host bone marrow derived cells (BMDCs), including myeloid cells
[21]. Nevertheless, as reviewed recently [22], direct roles for
macrophages in metastatic growth have not been reported. In this
paper using methods that are independent of the influence of the
primary tumors, we have tested the hypothesis that macrophages
are an important component of the microenvironment that control
the survival, migration and growth of metastatic cells. We used
different means of macrophage ablation together with an intact
lung imaging method and have shown that a population of
macrophages with a distinct phenotype is required for metastatic
extravasation, survival and growth. Importantly, we show that
macrophage depletion even inhibits the growth of established
metastatic nodules.
Results
CSF-1-regulated macrophages determine metastatic
efficiency
To test the hypothesis that macrophages regulate tumor cell
distal organ seeding and persistent growth, we performed
metastasis assays in a well established genetic model of
macrophage deficiency. In this model the macrophage deficiency
is caused by homozygosity of a null mutation (Csf1op) in the gene
for the major macrophage growth factor, colony stimulating
factor-1 (CSF-1) [23]. Initially in these studies, to avoid the
potential uniqueness of clonal cell lines, we used primary cultures
of tumor cells derived from mammary tumors that had been
caused by the mammary specific expression of the Polyoma
Middle T oncoprotein from the MMTV promoter [14]. Cultured
primary tumor cells prepared as described in the materials and
methods were harvested, carefully dissociated into single cell
suspensions and injected i.v. into syngeneic (FVB) host mice of
different genotypes for Csf1op. Tumors derived independently from
different mice give cells with widely varying metastatic capacity in
this assay as assessed in lungs harvested 14 days post-injection and
as expected since the tumor stage could not be completely
controlled (note the log scale on the Y axis, Figure 1D). However,
for every individual tumor cell isolate, a dramatic decline in
metastatic capacity was observed according to the allelic frequency
for the host Csf1op mutation (Figure 1A–C). Rigorous statistical
measurements using stereological techniques as defined numeri-
cally in the Materials and Methods, revealed that the metastatic
index for heterozygous mice was significantly lower than +/+ mice
and homozygous nulls had a significantly lower metastatic index
(total metastasis volume normalized to lung volume) than those
containing one or no mutant alleles (Fig. 1D). Both the numbers
(shown as metastasis number index, which equals to number of
metastasis nodules per mmˆ2 of lung area) (Figure 1F) and the size
of metastasis nodules (shown as mm) (Figure 1H) were reduced
according to Csf1op allelic frequency. We have also shown in the
past that CSF-1R is expressed in all macrophages and PyMT
tumor cells do not express the CSF-1 receptor (CSF-1R) [8,14]
and this was confirmed in the primary isolates of tumor cells used
in these experiments by RT-PCR (data not shown). This indicated
that the effect of CSF-1 depletion was not due to a direct effect of
CSF-1 on the tumor cells themselves but indicates that both
metastatic seeding and persistent growth of tumor cells are
dependent on macrophages.
To confirm this data with primary tumor cell isolates and to
control for the variation observed with primary cell cultures from
individual tumors, we repeated the metastasis assay using a highly
metastatic cell line, Met-1, derived from PyMT mouse mammary
tumor [24]. This cell line is also negative for CSF-1R expression
by RT-PCR (data not shown). The data with this cell line
confirmed that observed with primary tumor isolates and indicated
that the metastatic potential of Met-1 cells was reduced with both
seeding and persistent growth being significantly affected accord-
ing to the host CSF-1 deficiency (Figure 1E, G and I).
The metastatic index is a combination of cell survival and
proliferation. Thus to determine the apoptosis and proliferation of
the tumor cells in the lungs of mice with different genotypes, we
performed TUNEL and Ki67 staining on metastatic lesions 14
days post-injection as indices of apoptosis and proliferation
respectively. To avoid variations in non-clonal populations we
performed these studies with the Met-1 cell line. These cells
showed a significantly increased apoptotic rate according to the
host Csf1op allelic frequency with the homozygous null having the
highest rate of apoptosis (Figure S1 A and B). These data were also
confirmed with primary tumor isolates indicating that this was not
an effect of clonal selection (data not shown). These data suggests
that macrophages create an environment in the lung that
promotes tumor cell survival.
Transient macrophage depletion blocks tumor cell
metastasis
Mice homozygous for the Csf1op allele represent a genetic model
for macrophage deficiency. However, in this case the deficiency is
existent throughout life and it could be argued that the effect on
metastasis is secondary to a change in the lung microenvironment
caused by macrophage depletion during development. To assess
the consequences of an alternative way to deplete macrophages,
we used the well-established macrophage-ablation method of
treating mice in vivo with liposome encapsulated Clodronate
(dichloromethylene diphosphonate) made in-house as described
[25]. In parallel experiments performed by our collaborators and
us using subcutaneous xenografts showed that there was no uptake
of the liposome by PyMT tumor cells [26] and further liposome
encapsulated Clodronate did not kill cultured Met-1 cells (data not
shown). Consistent with the literature [25] our data showed two
injections of Liposomal-Clodronate i.v. was sufficient to deplete
macrophages in vivo (Figure S2 and data not shown) and we used
liposomal-PBS injection as a control and this had no impact on
macrophage numbers (not shown).
Using cumbersome imaging methods some studies have
estimated initial tumor cell survival and apoptosis [3,27].
However, most studies imprecisely measure the final metastatic
burden by using end-point assays and only counting the number of
metastasis nodules on the lung surface. To understand the initial
kinetics of surviving tumor cells once they reach the lung however,
we used a precise genomic DNA based quantitative real-time PCR
assay for the PyMT transgene (specific for tumor cells but not the
host non-transgenic cells) with DNA extracted from whole lung
digestions harvested at different time points after i.v. injection of
Met-1 cells. In this assay, a standard curve of cell number to Q-
PCR cycle threshold was generated so that an exact measure of
cell number in the lung could be made. Using this method
Macrophages and Metastasis
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Figure 1. Host CSF-1 determines tumor cell pulmonary seeding and persistent growth. (A–C) Different metastatic potential of primary
PyMT induced tumor cells shown in H&E stained transverse section of host lungs of different mouse genotypes. Wild type (wt), heterozygous Csf1op
(op/+) and homozygous Csf1op (op/op) (D–I) Quantifications of metastasis of primary PyMT tumor cells (D, F and H) and Met-1 cells (E, G and I) using
stereological methods. Metastasis index (D and E) is equal to total metastasis volume normalized by total lung volume (note log scale on Y axis in D);
Metastasis number index (F and G) is equal to averaged number of metastasis sites per mm2 lung area; Average diameter (H and I) is the averaged
size of metastasis nodules in millimeter. For primary PyMT cells n = 7, in each graph, data points in mice of different genotypes use the same symbol
for each individual tumor. For Met-1 cells data are shown as mean+SEM. n$4, *p,0.05, **P,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0006562.g001
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macrophage depleted mice treated with L-Clodronate were
compared to control L-PBS treated mice. In both cases there
was no effect on the lodging of tumor cells to the lung with over
85% of the injected tumor cells arriving there immediately after
the tail vein injection. In control mice the number dramatically
decreases with time until it reaches its nadir at 36 hours after
which the cell number starts to increase exponentially. This
kinetics clearly marks the seeding phase at around 36 hours post-
injection and their initial growth afterwards. In the macrophage
depleted mice, tumor cell number over the first 12 hours declined
at the same rate as the controls but in contrast to the controls,
thereafter it decreases more rapidly with significantly fewer cells
remaining in the lung at 36 hours. There was also significantly
fewer tumor cells at 48, 72 and 96 hours in the L-Clodronate
treated group (Figure 2A). Doubling times of tumor cell growth
following this initial 36 hour establishment period was 17.5 hours
in L-PBS treated mice and 34.4 hours in L-Clodronate treated
mice. Together, these data indicate that macrophages are critical
for both seeding and initial growth of metastatic tumor cells
consistent with the data using genetic depletion of macrophages.
To verify that the initial kinetics of tumor cell survival is
correlated with the final metastatic burden, the same experimental
metastasis assay as described in Figure 1 was preformed using Met-
1 cells but with L-Clodronate injected at different times post-
injection of tumor cells to deplete macrophages at different stages
of metastatic development (Figure 2B–D). Compared with the
control (L-PBS injection), macrophage depletion over the time of
tumor cell i.v. injection (L-Clodronate injection 16 hours before
and 2 hours after), greatly reduced the tumor’s metastatic potential
(Figure 2B), with both seeding and persistent growth inhibited
(Figure 2C and D). This is consistent with the lower seeding
efficiency and delayed growth of tumor cells in L-Clodronate
treated mice measured by Q-PCR method. Importantly depletion
of macrophages after tumor cell seeding with L-Clodronate
injection given at 48 hr and 96 hr or at 4 and 6 days also caused
a reduction in total metastasis burden in both cases (Figure 2B).
These treatments significantly limited tumor cell persistent growth
(measured by average diameter) (Figure 2D) but not the number of
metastatic nodules (Figure 2C). This shows that, as well as seeding
of the tumor cells, the growth of established metastatic nodules
even once seeding is completed can also be inhibited by
macrophage depletion.
A distinct macrophage population is recruited to lungs
bearing metastases
The above data strongly argues for a macrophage population
enhancing both seeding and persistent growth of metastatic cells.
In mice homozygous for the Csf1op mutation the lung resident
macrophage population is relatively normal in tissue distribution,
morphology, number and cell surface markers (Figure S3),
consistent with previous reports [28]. This is probably due to the
fact that the lung resident macrophages are largely regulated by
GM-CSF instead of CSF-1 [29]. In addition, deletion of alveolar
macrophage by intra-tracheal injection of L-Clodronate does not
affect Met-1 cell metastatic efficiency (data not shown). These data
strongly suggest that a distinct macrophage population is recruited
from the blood to the metastatic cells in lung. First to establish
whether macrophages are recruited to the pulmonary metastases,
immunohistochemical staining using anti-Mac3 (a macrophage
specific marker [30]) antibody was performed. In the experimen-
tally induced metastasis formed either by primary PyMT tumor
cells or Met-1 cells (Figure 3A, C), there was an abundant
infiltration of macrophages. This was not a cell-type or route of
injection specific phenomena because an intensive macrophage
infiltration was also seen in the spontaneous metastases derived
from late stage primary tumors of PyMT mice (Figure 3B) and in
spontaneous metastasis derived from a subcutaneously implanted
human breast cancer cell (MDA-231) in nude mice (Figure 3D).
These data show that macrophages are recruited to metastatic
lesions regardless of their origin.
Having established that macrophages are recruited to metastatic
lesions we next sought to define the characteristics of these
macrophages. To this end, we exploited a lineage marked mouse,
the MacGreen mouse, in which all macrophages and certain
neutrophils are labeled by GFP through expression from the CSF-
1R promoter [31] that we have re-derived on an FVB inbred
background. We performed FACS analysis of isolated Csf1r-eGFP
labeled cells and compared these cells from normal lungs with
those from lungs carrying experimentally induced metastasis from
Met-1 cells. Notably a distinct population of CD11b+Gr12
macrophages was consistently recruited by the pulmonary
metastasis while this population was essentially absent in normal
lungs (Figure 3E). In contrast, other haematopoietic cell
populations were not altered significantly by the presence of the
Met-1 metastatic lesions (Figure S4). To verify if macrophage
recruitment was restricted to experimentally induced metastasis,
we compared macrophages from normal lungs with macrophages
from lungs with visible spontaneous metastasis in PyMT transgenic
mice bearing late stage primary mammary tumors. The same
CD11b+Gr12 macrophage population was recruited by the
spontaneous metastatic lesions (Figure 3F). Thus these cells are
recruited to experimentally induced and spontaneous metastases.
In combination with another mouse macrophage marker, F4/80
[32], we verified that these cells are macrophages and that a
significant recruitment to the lungs appeared as early as 36 hours
after introduction of the tumor cells into the circulation (Figure
3G). Detailed immunophenotyping of this CSF-1R+population
shows that compared to normal lung resident macrophages (which
are CD11c+), this distinct CD11b+ Gr12 macrophage population
has similar F4/80 expression, dim CD11c+ expression, and strong
CX3CR1, CCR2 and VEGFR1 expression (Figure 3H). These
cells do not have detectable surface Tie2 or CXCR4 expression
(data not shown), which makes them distinct from previous
identified pro-angiogenic macrophages [33,34]. Both lung resident
macrophages and metastasis recruited macrophages also have
similar Mac3 expression verifying the IHC staining (Figure S5).
Deletion of CD11b+ macrophages in vivo inhibits
metastasis
To test whether the recruited CD11b+ macrophage population
has an important role in promoting metastasis, we took advantage
of a transgenic mouse expressing the human diphtheria toxin (DT)
receptor (DTR, also known as heparin-binding EGF; hb-EGF)
under the control of the a truncated mouse CD11b promoter
(CD11b-DTR), in which CD11b+F4/80+macrophages but not
neutrophils (that also express CD11b) can be conditionally ablated
upon DT injection [35]. To avoid problems in interpretation of
potential leaky expression of the transgene in non-haematopoietic
cells, we generated mosaic mice by bone marrow transplant using
CD11b-DTR mice as the bone marrow donors. Wild type into
wild type bone marrow transplants were used as transplantation
controls while a mutated inactive form of the DT (Glu52-DT) was
used as toxin control [36]. As expected, two DT injections given
over 48 hours greatly depleted the CD11b+macrophages in the
peripheral blood in the mice that received the transplantation of
bone marrow from CD11b-DTR mice, but had no effect on these
populations in wild type bone marrow transplant controls.
Similarly Glu52-DT treatment has no effect on the transgene
Macrophages and Metastasis
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mosaic animals showing the depletion is toxin dependent (Figure
4A). Other haematopoietic cell populations were not significantly
affected by DT treatment consistent with the macrophage
restricted expression of the truncated promoter (Figure S6). In
the lung, resident CD11c+macrophages were also not affected by
the DT injections consistent with their lack of CD11b expression
(Figure 4B).
Since CD11b+macrophages are recruited to the metastasis-
bearing lungs, we analyzed whether these cells are depleted
following DT injection. DT was injected at a time when significant
metastases were induced by Met-1 cells injection and when
CD11b cells are already recruited. As expected, CD11b+
macrophages (F4/80+) were specifically depleted in the peripheral
blood and in the metastasis-bearing lungs (Figure 4C and Figure
S7C). Another F4/80highCD11bhigh population, which has been
reported to be involved in B cell immune regulation [37], was
unaffected by this treatment however, suggesting that the
transgene was not being actively transcribed or translated in this
population despite the cells having CD11b expressed from the
endogenous gene (Figure 4C and Figure S7C). A change of
CD11b+Gr1+bone marrow derived suppressor cells probably pre-
granulocytes [38] were believed to be responsible for the reduced
metastasis of Lewis lung carcinoma cells in TLR22/2 mice [21].
However in our metastasis model, these cells are F4/80- and their
recruitment is not significantly different in metastasis bearing lungs
compared with normal lungs (data not shown). Furthermore, they
are not affected by DT treatment in metastasis bearing lungs
(Figure S7A and B)
Having established the potency of this diptheria transgene
method in depleting CD11b+ cells, we used it to deplete CD11b+
Figure 2. Macrophage depletion blocks tumor cell pulmonary seeding and persistent growth. (A) Absolute number of surviving tumor
cells in the lung at different time points indicated after the tail vein injection (n$3, *p,0.05). Open box, mice treated with liposome-PBS; solid
triangle, mice treated with liposome-Clodronate. Data are shown as mean6SEM. (B–D) In vivo macrophage depletion blocks tumor cell pulmonary
seeding and persistent growth. In-house prepared liposome-Clodronate was injected i.v. into the tail veins of mice at time indicated according to the
time of Met-1 cell injection to deplete macrophage in vivo. Metastasis quantification was the same as in Fig. 1. n$5, **P,0.01.
doi:10.1371/journal.pone.0006562.g002
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Figure 3. Recruitment of a distinct macrophage population in metastasis bearing lungs. (A–D) Pulmonary metastasis of breast cancer cells
are highly infiltrated with macrophages. Representative Mac3 immunohistochemistry staining of transverse sections of lung metastatic lesions from
different tumor models: (A) experimental metastasis of primary PyMT tumor cells; (B) spontaneous metastasis derived from a MMTV-PyMT induced
mammary tumor; (C) experimental metastasis of Met-1 cells and (D) spontaneous metastasis derived from subcutaneously implanted MDA-231 cells.
Bar equals 20 um. (E) Representative flow diagram of CSF-1R-GFP positive cells from normal lung (upper panel) and metastasis bearing lung from
experimental metastasis assay of Met-1 cells (lower panel). n = 5 (F) Representative flow diagram of CSF-1R-GFP positive cells from normal lung (upper
panel) and lung bearing spontaneous metastasis from MMTV-PyMT induced mouse mammary tumor (lower panel). n = 3 (G) Recruitment of
CD11b+Gr1- macrophages (F4/80+) in lungs with experimentally induced metastasis with Met-1 cells. Lungs were harvested at time indicated after
tumor cell i.v. injection. Data are shown as mean+SEM. n = 3, *p,0.05 and **P,0.01. (H) Representative flow histograms of normal lung macrophages
(F4/80+, blue dashed line) versus recruited macrophage population (F4/80+CD11b+Gr1-, red solid line) from lungs bearing Met-1 cell metastases
stained with antibodies of different cell surface makers (indicated at the right side of the histogram). X axis indicates the fluorescent intensity, Y axis
indicates the percentage of maximum cell number, MFI (top right panel) denotes representative mean fluorescent intensity (n = 3).
doi:10.1371/journal.pone.0006562.g003
Macrophages and Metastasis
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Figure 4. Ablation of CD11b+macrophages blocks tumor cell pulmonary seeding and persistent growth. (A) Representative flow
diagram of blood CD45+cells in mice treated with diphtheria toxin (DT) or Glu52 mutated DT. X axis, CD11b expression; Y axis, F4/80 expression. (B)
Representative flow diagram of lung F4/80+cells in mice treated with DT or Glu52-DT. X axis, CD11b expression; Y axis, CD11c expression. (C)
Representative flow diagram of lungs CD45+cells of mice with experimentally introduced Met-1 cell metastases before DT or Glu52-DT treatment. X
axis, F4/80 expression; Y axis, CD11b expression. (D–F) In vivo depletion of CD11b+macrophage blocks tumor cell pulmonary seeding and persistent
growth. DT was given i.p. at the times indicated according to Met-1 cell injection and metastasis quantifications were the same as in Fig. 1. DT
treatment on mice with wild type bone marrow transplant and Glu52-DT treatment on mosaic mice were used as controls. Data are shown as
mean+SEM. n$5, *p,0.05 and **P,0.01.
doi:10.1371/journal.pone.0006562.g004
Macrophages and Metastasis
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macrophages co-incident with the tumor cell injection (24 hours
before and 2 hour after injection). Compared with DT treatment
on wild type bone marrow transplant control, this treatment
greatly reduced the tumor cell metastatic potential, with both
seeding and persistent growth impaired (Figure 4D, 2nd histo-
gram). When the CD11b+ macrophage population was depleted
after tumor cell seeding had occurred (treated 2 and 4 day after
tumor cell i.v. injection) only the persistent growth of metastatic
tumor cells was reduced (Figure 4D, 3rd histogram), consistent with
the effects of macrophage depletion using L-Clodronate described
above. Treatment of bone marrow transplanted transgene-bearing
mice with the mutated toxin had no effect on tumor metastastic
potential (Figure 4D, 4th histogram). These data confirm the
requirement of macrophages for metastatic seeding and persistent
growth and further identify the recruited CD11b+ population as
the effector cells.
Host CD11b+Gr1- macrophages are critical for human
breast cancer cell experimental metastasis
To test the hypothesis that macrophage dependency is a general
phenomena for breast cancer pulmonary metastasis, experimental
metastasis assays were performed in nude mice using the
metastatic variants of MDA-231 human breast cancer cell lines,
3475 and 4173 (kind gifts from Dr. Joan Massague (MSKCC, New
York) [39]. In mice whose macrophages were depleted with L-
Clodronate, the metastatic potential of both cell lines was
significantly reduced, with both seeding and persistent growth
impaired (Figure 5A). Established metastatic nodules were also
highly infiltrated with macrophages (Figure 5B). Comparing F4/
80+ macrophages from metastasis-bearing lung with those from
healthy lungs, it was observed that a significant population of
CD11b+Gr1- macrophage population was recruited by the
metastases derived from both cell lines (Figure 5C). This
macrophage population has similar F4/80 expression with
macrophages from healthy lungs, but has a distinct phenotype of
CD11cdim CD11b+VEGFR1high and CCR2high (Figure 5D). In
addition, there is another but uncharacterized F4/80+ population
that is Gr1+ but CD11b-. The identity and function of these cells is
unknown but they are unique to these human cell lines.
Nevertheless, in metastasis derived from human breast cancer
cells, we can conclude that the same population of macrophages as
found in mouse metastases is required for efficient tumor cell
seeding and persistent growth.
Tumor cell -macrophage interaction is required for tumor
cell extravasation
Despite the considerable efforts that have been expended on
studying the interaction between metastasizing tumor cells and
blood vessel in target organs, no uniform conclusions have been
reached [40,41]. Thus to explore the role of the macrophages in
metastatic seeding and extravasation mechanistically, we used an
intact ex-vivo lung imaging system that preserves the physiological
lung structure [42]. In this system, Csf1r-EGFP transgenic mice
were injected i.v. with CFP-expressing Met-1 cells and harvested
at different times after injection. Dye conjugated anti-mouse CD31
antibody was injected i.v. to label blood vessels. Fluorescent
images of the resultant lungs were taken using a LeicaH confocal
microscope and 3D reconstructions that allowed precise measure-
ments of cell extravasation, macrophage number and area of
direct interaction with tumor cells were performed using
VolocityTM software. Representative images of at least three
separate experiments are shown in Figure 6A–E and 3D
reconstructed images are shown in supplemental movies.
Five minutes after tumor cell injection (Figure 6A, Movie S1),
numerous tumor cells have reached the lung vasculature consistent
with the Q-PCR data (Figure 2A). Most tumor cells were not
interacting with lung resident macrophages, although a few are
attached in the vessel to GFP-labeled cells with morphology
consistent with monocytes (Figure 7A left most histogram). At five
minutes, all tumor cells were retained in the vessel (Figure 7C left
most histogram). Some blood vessels were much larger than a
single cell diameter, suggesting active attachment of the tumor
cells rather than physical restraint although they may have been
surrounded by platelets that would not have been visualized in
these experiments. At 24 hours (Figure 6B and Movie S2), the
number of tumor cells remaining in the lung dramatically
decreased, consistent with the Q-PCR data. Importantly at this
time tumor cell and macrophage interactions dramatically
increased, measured by both the number of macrophages
interacting with each tumor cluster and the contact area between
these two cell types (Figure 7A and B). Interestingly, ,75% of the
surviving tumor cells are outside the vessel at this time (Figure 7C).
Tumor cells under-going extravasation (crossing the vessel) were
observed, with most of the extravasated part (Figure 6B, arrow
head) directly interacting with macrophages (Figure 6B and Movie
S2). At 48 and 72 hours, the majority of the tumor cells were
outside the vessel with an increasing number of interacting
macrophages (Fig 6C, D, Movie S3 and 4). At 72 hours, no cells
were observed to be completely inside the vessel (Figure 7C). Some
tumor clusters are larger than a single cell in dimension suggesting
cell proliferation, and these clusters have extensive macrophage
interactions (Figure 6D, 7D and Movie S4). Starting from
24 hours, tumor volume is positively correlated with macrophage
interaction area (Figure 7D and data not shown).
To further analyze the role of macrophages in these early
processes, similar experiments were performed but in this case
following macrophage depletion using L-Clodronate. Consistent
with the data in Figure 2 there were many fewer tumor cells
observable in the lung following macrophage depletion. Further-
more those that remained had virtually no interaction with
macrophages compared to that seen in control mice (Figure 7B).
Importantly the extravasation of tumor cells was delayed following
macrophage depletion such that at 24 hrs only ,25% were
extravascular compared to ,75% in the control mice and with
twice the number still entirely retained in the vessels (Figure 6E,
7C and Movie S5). By 48 hrs those few tumor cells that have
survived have mostly extravasated although significantly more are
still in process (Figure 7C). In contrast, tumor cell behavior in L-
PBS treated mice did not differ from untreated mice (data not
shown). These data therefore identify a unique mechanism for
macrophages in promoting tumor cell extravasation into the
metastatic site. In addition, these data combined with that in
Figure 2, show that tumor cells begin to proliferate once
extravasated and this proliferation is promoted by the association
of macrophages within the establishing metastatic nodules.
Together these data indicate that macrophages promote the
earliest steps in metastatic seeding in that they significantly
enhance the rate of tumor cell extravasation and survival.
Discussion
There is a growing body of evidence that indicates that
macrophages in the primary tumor promote tumor progression to
the metastatic phenotype [43]. This evidence comes from two
sources: 1) clinical correlative data that shows in over 80% of the cases
that a strong macrophage infiltrate is correlated with poor prognosis
[44]; 2) mouse models where genetic ablation of macrophages results
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in an inhibition of tumor progression and a reduced rate of metastasis
[14]. In part, this tumor promotion by macrophages is due to their
role in regulating angiogenesis [45] and to their ability to enhance
tumor cell motility, invasion and intravasation (reviewed in [11]).
These macrophage activities therefore increase the potential for
metastatic spread from the primary tumor not only by stimulating
tumor invasiveness but also increasing the number of target vessels
through which the tumor cells escape. These tumor-associated
macrophages have been described as trophic macrophages [46] or
M2 [47] since they have a phenotype that suggests developmental,
tissue remodeling as well as immune-regulatory functions that
suppress cytotoxic immune responses [48,49,50].
Macrophages have also been found associated with tumors at
metastatic sites [26]. Earlier studies attempted to determine
Figure 5. Host CD11b+Gr1- macrophages promote human breast cancer cell experimental metastasis. (A) In vivo macrophage depletion
by liposome encapsulated Clodronate blocks tumor cell pulmonary seeding and persistent growth of MDA-231 derived human breast cancer cell
lines, 3475 and 4173. Metastasis quantifications were the same as in Fig. 1. Data are shown as mean+SEM. n = 5, *p,0.05, **P,0.01 and ***p,0.001.
(B) Pulmonary metastases of human breast cancer cells in nude mice are highly infiltrated with macrophages with anti-Mac3 antibody staining as
described in methods. (C) Representative flow diagrams of CD11b+Gr1- cells recruitment by pulmonary metastases of 4173 and 3475. Lung F4/
80+cells were separated by surface expression of CD11b (X axis) and Gr1 (Y axis), n = 3 (D) A graph comparing flow cytometric data of mean
fluorescent intensity of different cell surface markers (F4/80, CD11b, CD11c, VEGFR1 and CCR2) expressed by normal lung macrophages (left
histogram) and macrophages recruited by pulmonary metastases of 3475 (middle histogram) and 4173 (right histogram). Data are shown as
mean+SEM. n = 3, *p,0.05, **P,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0006562.g005
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macrophage functions in distal metastasis events by their co-
injection with tumor cells. Although the injection of tumor cells
mimics the large number of tumor cells that are shed from late
stage tumors [51] mature macrophages are not observed in the
circulation. Thus this system remains artificial and contradictory
results have been observed [17,52]. Recent studies however have
indicated that bone marrow derived cells in addition to their roles
in the primary tumor also promote metastasis through their effects
Figure 6. Tumor-macrophage interaction in the lung using ex vivo imaging. Representative snapshots of 3D reconstructed confocal images
of tumor cell (CFP, shown in blue) and macrophage (GFP, shown in green) at different times indicated after tumor cell tail vein injection: 5 minutes
(A), 24 hours (B), 48 hours (C), 72 hours (D) and 24 hours in L-Clodronate treated mouse (E). Blood vessel were stained with Alexa FluorH 647
conjugated anti-mouse CD31 antibody (shown in red). Bar equals 20 um. Arrow heads in B indicate the extravasated part of the tumor cell.
doi:10.1371/journal.pone.0006562.g006
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at secondary sites. In particular, it has been shown that primary
tumors influence the selection of metastatic sites through the
secretion of factors that recruit bone marrow cells to these sites to
create the so-called pre-metastatic niche in which circulating
tumor cells settle and prosper [53,54]. The bone marrow cells that
populate these niches have not been fully characterized but are of
myeloid origin [55]. Despite these important studies, there remains
no direct evidence for macrophages influencing the events
subsequent to homing of metastatic cells [22]. To test whether
macrophages do have a role in these subsequent events, we used
an experimental metastasis model to circumvent the influence of
primary tumors. Using this system we show that macrophage play
a significant role in the extravasation of metastatic cells as well as
in their establishment and growth in the lung.
This conclusion that macrophages have a major impact on
metastatic cell seeding and persistent growth was based upon
studies using three different and independent methods of
macrophage ablation. The first used mice carrying a null mutation
(Csf1op) in the major macrophage growth factor, CSF-1, to deplete
the macrophages [56] and these studies showed a profound
inhibition of metastatic cell seeding and persistent growth.
Interestingly, there was an effect on the metastatic index (a sum
of metastasis number and size) according to the null allele
frequency. This is unusual since previous studies showed that
heterozygous mice have normal serum concentrations of CSF-1
and normal populations of macrophages in most tissues tested
[57]. Indeed in the lung we showed that+/Csf1op mice also have
normal resident macrophage numbers (Figure S3). However, a
radioimmuno-assay of lung tissue CSF-1 revealed a reduced CSF-
1 expression in the heterozygote (data not shown). This indicates
the strong dependence of host CSF-1 level for efficient tumor cell
seeding and growth in lung. It will be interesting to determine if a
heterozygote effect can be found in human populations with breast
cancer. It should be noted that increased levels of circulating CSF-
1 in human patients with breast, ovarian and endometrial cancer is
correlated with poor prognosis [58,59,60].
The second method of macrophage depletion used the classical
method of liposome-encapsulated Clodronate that causes macro-
phage death after its selective phagocytosis by mature macrophages
[25] but not by tumor or other cells [26]. When the macrophages
were depleted by this method spanning the period of metastasis
assay, both tumor cell seeding and persistent growth were inhibited.
Importantly macrophage depletion using this method after
metastatic seeding resulted in the reduction of metastatic growth.
The third method was based upon the observation (see results
and below) that the recruited macrophage population was different
from the lung resident CD11c+ macrophages in their expression of
CD11b. This enabled the use of a suicide gene approach whereby
the CD11b+positive macrophages were ablated by dint of their
expression of the diptheria toxin receptor from the CD11b
promoter [35]. Using this method we showed that this CD11b+po-
pulation of macrophages was required for both seeding and
persistent growth. Importantly the resident population of macro-
phages were unaffected by this treatment showing that it is the
newly recruited population that is responsible for the effects.
Furthermore similar to the data obtained following L-Clodronate
Figure 7. Tumor-macrophage interactions promotes tumor cell
extravasation and correlates with initial tumor growth. (A)
Average area of direct interaction between tumor cells and macro-
phages per tumor cluster measured by confocal microscopy at different
time points after iv injection. Statistically different from 5 min time
point *p,0.05, **P,0.01 and ***p,0.001 (B) Left four histograms:
Average number of macrophages that directly interact with each tumor
cell cluster at different time points after iv injection. Statistically
different from the 5 min control *p,0.05, **P,0.01. Right three
histograms: Interactions following macrophage depletion using Lipo-
some-Clodronate administered 16 hrs before and 2 hours after iv
injection as described in the materials and methods. All time points are
significantly lower than the macrophage replete mice. (C) Tumor cell
extravasation status at different time points after iv injection showing
the percentage of totally intravascular (red), extravasating (blue, inside
vessels and outside) and extravascular (yellow, completely outside
vessels) in normal or macrophage depleted mice using Liposome-
Clodronate as described above. Note that data is represented as a
percentage of total cells although the number of viable tumor cells is
greatly reduced after macrophage depletion (Fig. 2A). The delay in
extravasation at 24 hrs following macrophage depletion is statistically
significant with p,0.05. (D) Correlation between tumor cluster volume
and tumor-macrophage interaction area at 72 hours after tumor cell tail
vein injection. p,0.0001, R2 = 0.58 (A–C are based upon 3D images of
10–20 clusters per animal, 3–6 mice per time point. Data are shown as
mean+SEM. D., 51 tumor clusters from 3 mice).
doi:10.1371/journal.pone.0006562.g007
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ablation, depletion of these macrophages using the diptheria toxin
approach after the metastasis had been established also resulted in
inhibition of growth. Thus we can conclude from these three
approaches that the CD11b+population of mature macrophages
that is recruited to the lung in response to the arrival of metastatic
cells promote their subsequent establishment and growth. This
ability to inhibit the growth of metastases once established also
suggests that macrophage depletion will have significant therapeutic
potential.
Our data showed the recruited macrophage population is
characterized by a cell surface marker signature of F4/80+CSF-
1R+CD11b+Gr1-CX3CR1highCCR2high and VEGFR1high and
their recruitment to pulmonary metastases is independent of the
metastatic cell type or the species of origin (mouse and human). It
should also be noted that although this experimental model of
metastasis is somewhat artificial in that a bolus of cells arrives to the
lung within 5 minutes, a population of macrophages with a similar
phenotype is also recruited to spontaneous metastases derived either
from primary autochthonous mammary tumors or from xenotrans-
plants of human breast cancer cells in immunocompromized mice.
These macrophages display characteristic markers such as F4/80,
Mac3, CSF-1R and are phagocytic because they up-take liposomes
(see below) while being negative for granulocyte marker, Gr1. While
none of these markers are unique to macrophages in themselves, the
combination and their high level of expression together with the cells
tissue location indicates that these cells are definitive macrophages
[46]. They probably differentiate from monocytes precursors that are
restricted to blood and seed most macrophages but it cannot be ruled
out that they cross-differentiate from other resident macrophages as
has been described in some immune responses [61]. This metastasis-
associated CD11b+macrophage population is different from the
classically defined inflammatory Gr1+CCR2+CX3CR1low macro-
phages and Gr1-CCR2-CX3CR1high tissue macrophages [62] and is
also distinct from other recently identified macrophage populations in
the primary tumor microenvironment such as myeloid suppressor
and pro-angiogenic macrophages [11,63,64]. It is also different from
the populations found in the primary tumors of PyMT mice in the
expression of CXCR4 and Tie2 (our unpublished data). They are
however, similar to a recently identified anti-inflammatory macro-
phage important in facilitating myogenesis in terms of Gr1 expression
[65]. This distinct phenotypes give further support to the notion of the
tumor microenvironment educating the recruited macrophages to
give functions that are advantageous to the growing tumor cells [66].
Our data shows that macrophages not only affect metastatic
growth but also seeding. This ability of tumor cells to establish
themselves at the metastatic site is considered one of the major rate
limiting steps in metastasis [1]. But there is considerable
controversy about how tumor cells interact with blood vessels in
their metastatic target organ and the subsequent steps in
establishment [40]. Because of the unique vasculature in the lung,
conventional method of vessel labeling using dextran does not
work well since this molecule leaks out easily. Furthermore,
because lung is fragile, the vessel structure is often damaged during
fixation and sectioning. Thus to examine the early steps we used
an intact lung imaging system [42] with methods that visualizes
macrophages, blood vessels and tumor cells simultaneously
followed by detailed quantitative analysis of extravasation events
together with a QPCR method that accurately measures tumor
cell number. For these methods single cell suspensions were
carefully prepared to avoid emboli formation and these were not
observed in the lung vasculature after tumor cell injection. Indeed
as the individual tumor cells arrive in the lung they begin a process
of attachment and invasion. While this process is inefficient the
presence of the tumor cells stimulates the recruitment of
macrophages that form intimate contacts with them as soon as
they extrude through the vessel walls. Importantly, the rate of
extravasation of the tumor cells was significantly reduced after
macrophage depletion with a co-incident reduction in tumor cell
viability. Once extravasation is completed tumor cell proliferation
begins and there is a positive correlation of tumor cell growth with
macrophage association at these early stages. Consistent with this
role of macrophages in promoting growth, macrophage depletion
at this time resulted in a two-fold increase in the population
doubling time. Thus this novel imaging technique together with
rigorous quantification shows that extravasation can be a rate
limiting step in the metastatic process and also identifies this
population of macrophages as a component of the microenviron-
ment that plays a critical role in this step as well as in the
subsequent growth of the surviving tumor cells. Further this
imaging of early stage events in metastasis is consistent with our
end point stereological measurements that show macrophages
positively influence both tumor cell seeding and persistent growth.
Metastasis remains an intractable problem clinically and is
therefore the major cause of death in cancer patients. Based on the
data in current study, we suggest a model for the macrophage
enhancement of metastasis at the distal target organ (Figure 8).
Following arrest of the tumor cells in capillaries of metastasis target
organ, monocytes were quickly recruited and differentiated in situ
into metastasis associated macrophage phenotype with a distinctly
defined cell surface marker phenotype. This recruitment is at least
in part under the influence of locally synthesized CSF-1, a well-
documented growth and differentiation factor for macrophages. In
addition as these macrophages express receptors for CCL-2 and
VEGF (CCR2 and VEGFR1 respectively), both cytokines that are
chemotactic for macrophages, it is likely that such signaling
molecules will play a role in this recruitment process. These
CD11b+macrophages recognizes extravasating tumor cells and
our imaging shows that they interact with them directly and help
them invade into the lung parenchyma. This is presumably
through the secretion of proteases, growth, and motility and
survival factors. In the absence of these newly differentiated
macrophages, this process of tumor cell extravasation is very
inefficient and the tumor cells rapidly die by apoptosis and thus the
seeding efficiency is very low. Once extravascular the tumor cells
continue to send signals to recruit and also possibly influence the
differentiation of the macrophages into trophic ones [46] that
further enhance tumor cell viability and growth. When the tumors
attain a certain size these macrophages are also likely to provide
angiogenic factors as they have been documented to do in the
primary tumor [45] that then help in the vascularization needed
for continuous metastatic growth. In this scenario several
macrophage signaling pathways and functions are likely to be
engaged at the different steps of tumor cell seeding, initial and
persistent growth. These are continuous process and overlapping
processes as ablation of macrophages after the metastatic lesions
are established retards their growth significantly. These data
suggests that macrophages themselves or their unique signaling
pathways represent new therapeutic targets that may be efficacious
in reducing cancer mortality.
Materials and Methods
Animals
Ethics statement. All procedures involving mice were
conducted in accordance with National Institutes of Health
regulations concerning the use and care of experimental
animals. The study of mice was approved by the Albert Einstein
College of Medicine Animal Use Committee.
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All transgenic mice were kept on the FVB background.
Transgenic mice expressing the PyMT oncogene under the control
of MMTV LTR were provided by Dr. W.J. Muller (McMaster
University, Ontario, Canada) and bred in house. Detailed
descriptions of the origin, care, and identification of Csf1op/Csf1op
(designated op/op in figures) mice and their heterozygote controls
have been given previously [57]. Csf1o/op mice were backcrossed into
FVB background in house for 10 generations (courtesy of E. R.
Stanley, Albert Einstein College of Medicine). Then male +/Csf1op
mice were randomly bred with +/Csf1op females to obtain female
Figure 8. Model for macrophage promotion of metastasis at distant sites. Based on the data in current study, we suggest a model for the
macrophage enhancement of metastasis at the distal target organ. Following arrest of the tumor cells in capillaries of metastasis target organ,
monocytes are quickly recruited and differentiate in situ into metastasis associated macrophage phenotype whereafter they promote the different
steps of metastatic seeding, initial and persistent growth as indicated in the figure and described in the discussion. Figure modified from Joyce and
Pollard, 2009.
doi:10.1371/journal.pone.0006562.g008
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mice of Csf1op/op, +/Csf1op or +/+background. Tg(Csf1r-EGFP)Hume
mice have been previously reported to have the whole mononuclear
phagocyte system labeled [31] and were remade on the FVB
background FVB.(tg(Csf1r-EGFP)1Jwp) with similar results. Trans-
genic mouse expressing human hbEGF driven by CD11b promoter
(tg(CD11b-DTR)Llan) is a previously reported model for effective in
vivo transient CD11b-expressing macrophage depletion. [35,67]
Homozygous animals were bred in house and were used as bone
marrow donors to generate chimeras with lethally irradiated 3 week-
old FVB females (Charles River, MA). Control chimeras were
generated using wild type bone marrow donor. Diptheria toxin (DT)
(Sigma-Aldrich, MO) was given i.p. at a dose of 50 ng per gram of
body weight in PBS, and Glu52-DT was give at the same dose.
Cell Culture
All cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum. The cultured
cells were confirmed to be mycoplasma negative by PCR
(Mycoplasma detection kit, Sigma, MO). To obtain primary tumor
cells, late stage tumors of 16 week old MMTV-PyMT FVB females
were harvested and minced using a razor blade, then digested using
collagenase A, 2 mg/ml and hyluronidase 100 unit/ml (Worthing-
ton, NJ) at 37uC for 1 hour. Cell suspension was passed through
40 um nylon filter (Fisher, PA) before transfer into culture dishes.
Non-attached cells and debris were flushed away the second day
and the remaining cells were passaged twice with 1 to 5 dilution and
cultured for five days before being carefully dissociated to give single
cell suspensions and introduced i.v. into host animals.
Lung Metastasis Assay
8-week-old FVB females or 6-week-old female nudemice were used
for all experimental metastasis assays with 56105 PyMT induced
tumor cells and 106MDA231 derived human tumor cells respectively.
If not specified, all animals were sacrificed 2 weeks after I.V. injection
of PyMT cells or 4 weeks for human tumor cells for optimal metastatic
burden. For paraffin sections, before removal, lungs were injected with
1.2 ml of 10% neutral buffered formalin by tracheal cannulation in
order to fix the inner airspaces and inflate the lung lobes. Lungs were
then excised and fixed in formalin overnight. A precise stereological
method [68] with slight modification was used for lung metastasis
quantification. Briefly, paraffin-embedded lungs were systematically
sectioned through the entire lung with one 5 um section taken in every
0.5 mm lung thickness. All the sections were stained with H&E and
images were taken using a Zeiss SV11 microscope with a Retiga 1300
digital camera and analyzed using ImageJ software.Mac3 (Santa Cruz
Biotech., CA) and F4/80 (CALTAG Laboratories) were used for
immunohistochemistry staining.
For realtime PCR based quantification of metastatic cells, lungs
were harvested at times specified after tumor cell i.v. injection
(zero time point was taken at 5 minutes post i.v.), minced, then
digested thoroughly with proteinase K. DNA were extracted using
DNAeasy Kit (Qiagen). Based on standards prepared in the same
way, absolute cell number was quantified by realtime quantitative
PCR (Opticon2, MJ/Bio-rad) with specific primers against PyMT
transgene. Primers sequences were a kind gift from Dr. Mike
Ostrowski (Ohio State University, Ohio).
Liposomal clodronate preparation and administration
Liposomal encapsulation of clodronate (dichloromethylene dipho-
sphonate) was performed as described previously [25] with slight
modification. Briefly, a mixture of 8 mg cholesterol (Avanti, Alabaster,
AL) and 86 mg egg-phosphatidylcholine (dioleoyl-phosphatidylcho-
line, Avanti, Alabaster, AL) was dissolved in methanol/chloroform (1:9
volume ratio) and then the thin-layer lipid membrane was made by
rotor-evaporation under nitrogen protection. The clodronate solution
was prepared by dissolving 1.2 g dichloromethylene diphosphonic acid
(Sigma Chemical Co.) in 5 ml sterile phosphate-buffered saline, then
added to the thin-layer lipid membrane and hydrated for 2 hours at 50
rpm in room temperature. The non-encapsulated chemical was
removed by dialysis with Slide-A-Lyzer (Pierce, Rockford IL) and 4L of
PBS (refreshed twice in 24 h). The final concentration of clodronate in
the liposome formulation was adjusted to 6 mg/ml. A single dose of
liposomal clodronate of 0.1 ml/10 g body weight was administered via
i.v. or intra-trachea injection at the times specified.
FACS analysis
For FACS analysis, lungs were perfused briefly with cold PBS
before harvest and then minced on ice. Cells were blocked using
anti-mouse CD16/CD32 antibody (eBiosciences, CA) before
antibody staining. Antibody used are: CD45 (30-F11), CD11b
(M1/70), CD11c (HL3), Gr1 (RB6-8C5), CXCR4 (2B11) (BD
Pharmingen); Tie2 (TEK4) (eBioscience); CX3CR1 (Torrey Pines
Biolabs, TX), VEGFR1 (141522), CCR2 (48607) (R&D systems),
and F4/80 (Cl:A3-1) (AbD Serotec). FACS analysis was preformed
on a LSRII cytometer (BD biosciences) and data were analyzed
using Flowjo software (TreeStar, OR)
Ex vivo whole lung imaging
A well established intact lung microscopy technique [42,69] was
applied to observe tumor cells, macrophages, and blood vessels in the
mouse lungs. CFP-expressing Met-1 cells prepared by retrovirus
infection of a CMV promoter-CFP vector were injected i.v. into the
tail vein of each mouse. At the time indicated, mice were anesthetized
and injected with 10 ug Alexa FluorH 647 conjugated anti-mouse
CD31 antibody (BioLegend, CA). Five minutes later, the mouse was
put under artificial ventilation through trachea cannulation. The lung
was cleared of blood by gravity perfusion through the pulmonary
artery with artificial medium [Krebs-Ringer bicarbonate buffer with
5% dextran and 10 mmol/L glucose (pH 7.4)]. The heart–lung
preparation was dissected en bloc and placed in a specially designed
plexiglass chamber with a port to the artificial cannula. The lung
rested on a plexiglass window at the bottom of the chamber with the
posterior surface of the lung touching the plexiglass. The lung was
ventilated throughout the experiment with 5% CO2 in medical air
and perfused by gravity perfusion except during imaging. Three to
five animals were imaged for each time point and 10 to 20 unrelated
fields were imaged for each animal.
Images were collected with a Leica TCS SP2 AOBS confocal
microscope (Mannheim, Germany) with 606oil immersion optics.
Laser lines at 458 nm, 488 nm and 633 nm for excitation of CFP,
GFP and AF647 were provided by an Ar laser and a HeNe laser.
Detection ranges were set to eliminate crosstalk between
fluorophores. Three-dimensional reconstruction was performed
using VolocityTM (Improvision Inc., MA) and self-developed
macros in ImageJ [70] were used for quantification.
Statistical analysis
Statistical analysis methods employed were repeated measures
ANOVA for primary PyMT tumor cells; standard two-tailed
Student’s t test for two data sets and ANOVA followed by
Bonferroni/Dunn post-hoc tests for multiple data sets using Prism
(GraphPad Inc.). p values below 0.05 (*), ,0.01 (**) and ,0.001
(***) were deemed as significant and highly significant, respectively.
Supporting Information
Figure S1 Increased apoptosis of metastasizing tumor cells in
CSF-1 deficient hosts. Apoptosis (Tunel) and proliferation (Ki67)
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of metastasizing Met-1 tumor cells in lungs of mice with different
genotypes as shown. Apoptosis index (A) and proliferation index
(C) are percentage of positive cells in total tumor cells. Data are
shown as mean + SEM. nm, ** P,0.01 and *** P,0.001.
Found at: doi:10.1371/journal.pone.0006562.s001 (5.33 MB TIF)
Figure S2 In vivo macrophage depletion using in-house-made
liposome -encapsulated Clodronate. Representative micrograph of
F4/80 immunostaining of liver sections from mice treated with
liposome containing PBS (L-PBS, left) and Clodronate (L-
Clodronate, right) as described in the materials and methods
indicates a dramatic macrophage depletion in the L-Clodronate
treated mice. Bar equals 20 um.
Found at: doi:10.1371/journal.pone.0006562.s002 (5.25 MB TIF)
Figure S3 Pulmonary macrophage populations are relatively
normal in Csf-1op/op mice. (A, C) Representative micrograph of
Mac3 stained lung m sections of lungs from mice with resident
macrophages in sagittal 5 genotypes shown; (B, D) Representative
Giemsa staining of cytospins of alveolar macrophages obtained by
lavage in the same mouse genotypes as in A, C, bar = 20um; (E)
Graph showing flow cytometric data of percentage of EGFP+
macrophages in total CD45 + cells in lungs of mice of different
genotypes designated as in Fig. 1 Data are shown as mean + SEM.
n=3, * p,0.05; (F) Graph showing cytometric data of the
percentage of CD11c + CD11b- cells in total Csf-1R-EGFP+ cells
in lungs of Tg (Csf1r-eGFP) Hume transgenic mice of different
genotypes designated as in Fig. 1. Data are shown as mean + SEM.
n=3.
Found at: doi:10.1371/journal.pone.0006562.s003 (11.87 MB
TIF)
Figure S4 Lymphocyte and granulocyte populations are not
significantly altered in lungs bearing experimental metastasis of
Met-1 cells. Bar graphs showing quantitative measurements of flow
cytometric data comparing cells with different surface markers as
shown from normal lungs and lungs bearing experimentally
induced metastasis of Met-1 cells. There were no significant
differences between groups. Data are shown as mean + SEM. n= 3.
Found at: doi:10.1371/journal.pone.0006562.s004 (4.08 MB TIF)
Figure S5 Lung resident macrophages and metastasis recruited
macrophages have similar Mac3 expression. Representative flow
histograms of normal lung macrophages (F4/80+, blue) versus
recruited macrophage population (F4/80+CD11b+Gr1-, red)
from lungs bearing Met-1 cell metastases stained with anti-Mac3
antibodies. X axis indicates the fluorescent intensity, Y axis
indicates the percentage of maximum cell number. (n = 3).
Found at: doi:10.1371/journal.pone.0006562.s005 (6.88 MB TIF)
Figure S6 CD11b+ macrophages are specifically depleted in
CD11b-DTR mosaic mice. Lymphocyte populations in blood of
bone marrow chimeras carrying the Diptheria toxin receptor
transgene are not affected by DT treatment compared to Glu52-
DT treatment while CD11b+ macrophages are specifically
depleted by the former treatment. Bar graph showing quantative
measurements of flow cytometric data comparing blood cells from
CD11b-DTR bone marrow mosaic mice treated with DT or
Glu52-DT. Data are shown as mean+ SEM. n=33, ** P,0.01
Found at: doi:10.1371/journal.pone.0006562.s006 (5.05 MB TIF)
Figure S7 CD11b+ Gr1+ cells are not depleted by diphtheria
toxin (DT) treatment in vivo. (A) Representative flow diagram of
CD45+ cells in lungs of mice in which significant lung metastasis has
been established by experimentally introducedMet-1 cells into bone
marrow chimeras carrying the Diptheria toxin transgene (Mosaic)
or wild type (WT) bone marrow as shown before DT or Glu52-DT
treatment. X axis, CD11b expression; Y axis, Gr1 expression.(B)
Graph showing flow cytometric data of the percentage of CD11b+
Gr1+ cells in the CD45+ population in lungs of mice in which
significant lung metastasis has been established.
Found at: doi:10.1371/journal.pone.0006562.s007 (9.79 MB TIF)
Movie S1 Tumor cell attaching to the blood vessel in lung at 5
minutes after tail vein inoculation.
Found at: doi:10.1371/journal.pone.0006562.s008 (0.90 MB AVI)
Movie S2 Extravasating tumor cell interacting with macrophag-
es at 24 hours after tail vein inoculation.
Found at: doi:10.1371/journal.pone.0006562.s009 (0.81 MB AVI)
Movie S3 Extravasated tumor cell interacting with macrophages
outside blood vessel at 48 hours after tail vein inoculation.
Found at: doi:10.1371/journal.pone.0006562.s010 (0.79 MB AVI)
Movie S4 Tumor cell cluster interacting with macrophages
outside blood vessel at 72 hours after tail vein inoculation.
Found at: doi:10.1371/journal.pone.0006562.s011 (0.94 MB AVI)
Movie S5 Tumor cell fail to extravasate with liposome
Clodronate treatment depleting interacting macrophage at
24 hours after tail vein inoculation.
Found at: doi:10.1371/journal.pone.0006562.s012 (0.61 MB AVI)
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